HomeFile

File

FFR and IFR: Are We Talking About the Same Thing?

To evaluate borderline coronary lesions (a 40% to 70% obstruction), determining associated ischemia is paramount. For this...

Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent...

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized...

When is the Ideal Timing for NSTE-ACS Percutaneous Intervention?

According to the European Society of Cardiology (ESC Guidelines 2021) an early invasive strategy is recommended (<24h)...

Should We Start Thinking Again About Bioresorbable Stents?

Coronary revascularization with drug-eluting stents (DES) is very frequent, especially in acute coronary syndromes, but these metallic...

A Nod to Catheter-Guided Thrombolysis in Pulmonary Thromboembolism

Pulmonary thromboembolism (PTE) is the third most frequent cardiovascular disease, with an increasing prevalence over time. The...

Post-MitraClip Mitral Valve Stenosis: Bad Prognosis

The EVEREST II trial has shown the MitraClip has similar mortality rate to that of surgery and,...

New-Generation ACURATE Neo2

Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current...